These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2143599)

  • 1. [The French ambulatory multicenter trial of Triatec: conclusions of the trial].
    Le Menn G
    Rev Prat; 1990 Jun; 40(18 Suppl):48-50. PubMed ID: 2143599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of Triatec in monotherapy and in combination with Lasilix in a French multicenter study].
    Guyot D; Lemarié JC
    Rev Prat; 1990 Jun; 40(18 Suppl):27-30, 35-8. PubMed ID: 2143596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [French multicenter study of Triatec (ramipril) in ambulatory patients: methodology and trial structure].
    Vasmant D; Thiéry P
    Rev Prat; 1990 Jun; 40(18 Suppl):21-6. PubMed ID: 2143595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ambulatory multicenter study of Triatec (ramipril). Observations concerning the lessons of the trial for the realization of future trials and for the management of hypertensive patients].
    Battaglia C; Gallet M; Carré A
    Rev Prat; 1990 Jun; 40(18 Suppl):45-7. PubMed ID: 2143598
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tolerance to Triatec in monotherapy and in combination with Lasilix in a French multicenter study].
    Elmalem J
    Rev Prat; 1990 Jun; 40(18 Suppl):39-44. PubMed ID: 2143597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension.
    Schnaper HW
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S128-30. PubMed ID: 1725021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.
    Kaneko Y; Omae T; Yoshinaga K; Iimura O; Inagaki Y; Ishii M; Saruta T; Yamada K; Kumahara Y; Ito K
    Am J Cardiol; 1987 Apr; 59(10):86D-91D. PubMed ID: 3034040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of ramipril on ambulatory blood pressure: a multicenter trial.
    Burris JF
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S131-3. PubMed ID: 1725022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.
    Vasmant D; Bender N
    J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S46-52. PubMed ID: 2483429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
    Böhm RO; van Baak MA; Rahn KH
    Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
    Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
    Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
    Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
    Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
    Bauer B; Lorenz H; Zahlten R
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S70-4. PubMed ID: 2474109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of response rates to the angiotensin-converting enzyme inhibitor ramipril in mild-to-moderate hypertension in a double-blind, parallel-group study and an open single-blind study.
    Vasmant D; Lendresse P; Lemarie JC; Gallet M
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S144-6. PubMed ID: 1725027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril.
    Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
    Am J Cardiol; 1988 Aug; 62(4):239-45. PubMed ID: 2969671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of ramipril in a multicenter study of mild-to-moderate hypertension in general practice.
    Carré A; Vasmant D; Elmalem J; Thiéry P
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S141-3. PubMed ID: 1725026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.
    Stumpe KO; Overlack A; Kolloch R; Schatz J; Witte PU; Pahnke K
    Klin Wochenschr; 1986 Jun; 64(12):558-62. PubMed ID: 3016405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of ramipril.
    Ball SG; Robertson JI
    Am J Cardiol; 1987 Apr; 59(10):23D-27D. PubMed ID: 3034028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramipril: a review of the new ACE inhibitor.
    Mills TP
    J Ark Med Soc; 1992 Feb; 88(9):437-40. PubMed ID: 1532570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial.
    Mroczek WJ
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S147-9. PubMed ID: 1725028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.